Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Plaque Psoriasis - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Chronic Plaque Psoriasis - Pipeline Review, H1 2015', provides an overview of the Chronic Plaque Psoriasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Plaque Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Plaque Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Chronic Plaque Psoriasis Overview 8 Therapeutics Development 9 Pipeline Products for Chronic Plaque Psoriasis - Overview 9 Pipeline Products for Chronic Plaque Psoriasis - Comparative Analysis 10 Chronic Plaque Psoriasis - Therapeutics under Development by Companies 11 Chronic Plaque Psoriasis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Chronic Plaque Psoriasis - Products under Development by Companies 15 Chronic Plaque Psoriasis - Companies Involved in Therapeutics Development 16 AbGenomics International, Inc. 16 Actelion Ltd 17 Almirall, S.A. 18 ApoPharma Inc. 19 Biotest AG 20 Boehringer Ingelheim GmbH 21 Can-Fite BioPharma Ltd. 22 Coherus BioSciences, Inc. 23 Covagen AG 24 Eli Lilly and Company 25 GlaxoSmithKline plc 26 Mitsubishi Tanabe Pharma Corporation 27 Novartis AG 28 OPKO Health, Inc. 29 Pfizer Inc. 30 Sandoz Inc. 31 Sun Pharmaceutical Industries Inc. 32 Takeda Pharmaceutical Company Limited 33 UCB S.A. 34 XenoPort, Inc. 35 Chronic Plaque Psoriasis - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 AbGn-168H - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 adalimumab biosimilar - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 baricitinib - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 BI-655066 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 certolizumab pegol - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 CF-101 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 CJM-112 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 COVA-322 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 dimethyl fumarate - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 etanercept biosimilar - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 etanercept biosimilar - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 GSK-2831781 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ixekizumab - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 lunacalcipol - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 MT-1303 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 namilumab - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 orilotimod - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 PF-06263276 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 ponesimod - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 tildrakizumab - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 tregalizumab - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 XP-23829 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Chronic Plaque Psoriasis - Recent Pipeline Updates 80 Chronic Plaque Psoriasis - Dormant Projects 102 Chronic Plaque Psoriasis - Discontinued Products 103 Chronic Plaque Psoriasis - Product Development Milestones 104 Featured News & Press Releases 104 Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis 104 Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 104 Nov 24, 2011: Biotest Announces Completion Of Phase IIa Trial Of Tregalizumab In Chronic Plaque Psoriasis 106 Appendix 108 Methodology 108 Coverage 108 Secondary Research 108 Primary Research 108 Expert Panel Validation 108 Contact Us 109 Disclaimer 109
List of Tables Number of Products under Development for Chronic Plaque Psoriasis, H1 2015 9 Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Chronic Plaque Psoriasis - Pipeline by AbGenomics International, Inc., H1 2015 16 Chronic Plaque Psoriasis - Pipeline by Actelion Ltd, H1 2015 17 Chronic Plaque Psoriasis - Pipeline by Almirall, S.A., H1 2015 18 Chronic Plaque Psoriasis - Pipeline by ApoPharma Inc., H1 2015 19 Chronic Plaque Psoriasis - Pipeline by Biotest AG, H1 2015 20 Chronic Plaque Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 21 Chronic Plaque Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H1 2015 22 Chronic Plaque Psoriasis - Pipeline by Coherus BioSciences, Inc., H1 2015 23 Chronic Plaque Psoriasis - Pipeline by Covagen AG, H1 2015 24 Chronic Plaque Psoriasis - Pipeline by Eli Lilly and Company, H1 2015 25 Chronic Plaque Psoriasis - Pipeline by GlaxoSmithKline plc, H1 2015 26 Chronic Plaque Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 27 Chronic Plaque Psoriasis - Pipeline by Novartis AG, H1 2015 28 Chronic Plaque Psoriasis - Pipeline by OPKO Health, Inc., H1 2015 29 Chronic Plaque Psoriasis - Pipeline by Pfizer Inc., H1 2015 30 Chronic Plaque Psoriasis - Pipeline by Sandoz Inc., H1 2015 31 Chronic Plaque Psoriasis - Pipeline by Sun Pharmaceutical Industries Inc., H1 2015 32 Chronic Plaque Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 33 Chronic Plaque Psoriasis - Pipeline by UCB S.A., H1 2015 34 Chronic Plaque Psoriasis - Pipeline by XenoPort, Inc., H1 2015 35 Assessment by Monotherapy Products, H1 2015 36 Number of Products by Stage and Target, H1 2015 38 Number of Products by Stage and Mechanism of Action, H1 2015 40 Number of Products by Stage and Route of Administration, H1 2015 42 Number of Products by Stage and Molecule Type, H1 2015 44 Chronic Plaque Psoriasis Therapeutics - Recent Pipeline Updates, H1 2015 80 Chronic Plaque Psoriasis - Dormant Projects, H1 2015 102 Chronic Plaque Psoriasis - Discontinued Products, H1 2015 103
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
